Comparison
Eloralintide vs. Pemvidutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
no data
Molecular weight
no data
no data
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Eloralintide
Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.
Pemvidutide
The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
2
1
of which in humans
1
1
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Eloralintide and Pemvidutide?
- Eloralintide is classified as "Metabolic", while Pemvidutide is classified as "Metabolic". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Eloralintide or Pemvidutide?
- The highest available evidence level is "Human RCT" for Eloralintide and "Human trial" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Eloralintide and Pemvidutide in Germany and the United States?
- Germany: Eloralintide — Unapproved, Pemvidutide — Unapproved. United States: Eloralintide — Unapproved, Pemvidutide — Unapproved. These are factual summaries with source and review date on the individual pages.